J. Goldman & Co’s Keros Therapeutics KROS Stock Holding History

J. Goldman & Co’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-54,236	Closed	-$2.82M	–	553
2024 Q3	$3.15M	Buy	54,236 +24,134	+80%	+$1.19M	0.09%	203
2024 Q2	$1.38M	Buy	+30,102	New	+$1.62M	0.04%	280
2024 Q1	–	Sell	-5,802	Closed	-$231K	–	462
2023 Q4	$231K	Buy	+5,802	New	+$182K	0.01%	295
2023 Q3	–	Sell	-7,677	Closed	-$308K	–	426
2023 Q2	$308K	Buy	7,677 +355	+5%	+$15.6K	0.01%	311
2023 Q1	$313K	Sell	7,322 -16,959	-70%	-$857K	0.01%	296
2022 Q4	$1.17M	Buy	24,281 +15,865	+189%	+$741K	0.06%	215
2022 Q3	$317K	Buy	+8,416	New	+$292K	0.02%	316

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's KROS Position: Q4 2024 in Review

J. Goldman & Co sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 54,236 shares — an estimated $2.82M sold.

J. Goldman & Co first reported a position in KROS in Q3 2022 and held it in 7 quarters. The position peaked at $3.15M in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

J. Goldman & Co reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
J. Goldman & Co sold 54,236 Keros Therapeutics shares in Q4 2024, an estimated $2.82M.
J. Goldman & Co first reported a position in Keros Therapeutics in Q3 2022 and held it in 7 quarters.
J. Goldman & Co's Keros Therapeutics position peaked at $3.15M in Q3 2024.
161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.